Literature DB >> 19422442

Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia.

T Bakchoul1, A Giptner, A Najaoui, G Bein, S Santoso, U J H Sachs.   

Abstract

BACKGROUND: Heparin-induced thrombocytopenia (HIT) is an adverse complication of heparin caused by HIT antibodies that recognize platelet factor 4-heparin (PF4/hep) complexes leading to platelet activation. Several methods are available for the identification of HIT antibodies.
OBJECTIVES: To evaluate the clinical usefulness of different antigen-binding assays for detection of antibodies against PF4/hep complexes in a prospective study. PATIENTS/
METHODS: A prospective cohort of 500 surgical and medical patients suspected of having HIT was evaluated. The laboratory assessment included particle gel immunoassay (PaGIA), polyspecific ELISA recognizing IgG, IgM and IgA antibodies (Poly-ELISA), IgG-specific ELISA (IgG-ELISA) and the HIPA test. The pretest probability of HIT was determined using the 4T's model. Positive and negative predictive values (PPV, NPV) of each immunoassay were determined depending upon the heparin-induced platelet activation (HIPA) results and the clinical scoring. The operating characteristics of each immunoassay were determined using the receiver-operation characteristic (ROC) curve.
RESULTS: Platelet-activating antibodies were identified in 35/500 patients, all of whom had intermediate to high clinical probability. PF4/hep antibodies were detected in 124, 86 and 90 sera using Poly-ELISA (PPV = 28), IgG-ELISA (PPV = 40.6) and PaGIA (PPV = 36.6). NPV was 100% for Poly- and IgG-ELISA, but only 99.5% for PaGIA. ROC analysis revealed that PaGIA is less informative than ELISA. The IgG-ELISA provides better diagnostic information than the other assays. In addition, there is a clear correlation between optical density (OD) value and the probability of having HIT.
CONCLUSIONS: Our observation indicates that an IgG-ELISA provides the best diagnostic information of all antigen-binding assays.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422442     DOI: 10.1111/j.1538-7836.2009.03465.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  26 in total

Review 1.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Heparin-induced thrombocytopenia.

Authors:  Grace M Lee; Gowthami M Arepally
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

3.  Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients.

Authors:  Vanessa Nellen; Irmela Sulzer; Gabriela Barizzi; Bernhard Lämmle; Lorenzo Alberio
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

4.  Platelet factor 4/heparin-particle gel immunoassay (PaGIA) is a weak method for heparin-induced thrombocytopenia (HIT) evaluation of post cardio-pulmonary bypass surgery patients.

Authors:  Chezi Ganzel; Jacob Rowe; David Raveh
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

5.  Over-testing for heparin induced thrombocytopenia in hospitalized patients.

Authors:  Shruti Chaturvedi; Ruhail Kohli; Keith McCrae
Journal:  J Thromb Thrombolysis       Date:  2015-07       Impact factor: 2.300

6.  Progressive thrombocytopenia after cardiac surgery in a 67-year-old man.

Authors:  Ilana Kopolovic; Theodore E Warkentin
Journal:  CMAJ       Date:  2014-04-22       Impact factor: 8.262

Review 7.  Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.

Authors:  Connie N Hess; Richard C Becker; John H Alexander; Renato D Lopes
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

Review 8.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

Review 9.  Diagnosis and management of heparin-induced thrombocytopenia.

Authors:  Grace M Lee; Gowthami M Arepally
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-13       Impact factor: 3.722

10.  Novel diagnostic assays for heparin-induced thrombocytopenia.

Authors:  Adam Cuker; Ann H Rux; Jillian L Hinds; May Dela Cruz; Serge V Yarovoi; Isola A M Brown; Wei Yang; Barbara A Konkle; Gowthami M Arepally; Stephen P Watson; Douglas B Cines; Bruce S Sachais
Journal:  Blood       Date:  2013-02-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.